Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Action of Calcium Channel Blockers

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The sarcopenia and frailty conundrum in heart failure: a clinical perspective from the FREE registry.

Acta cardiologica·2026

Same author

Systemic inflammatory profiles are associated with long-term kidney failure and patient mortality in chronic kidney disease.

Clinical kidney journal·2026

Same author

Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients.

iScience·2025

Same author

Two decades of global tobacco control: time for a rethink.

Internal and emergency medicine·2025

Same author

Long-Term Effect of Semaglutide on the Glomerular Filtration Rate Slope in High-Risk Patients with Diabetic Nephropathy: Analysis in Real-World Clinical Practice.

Pharmaceutics·2025

Same author

New Drugs for Resistant Hypertension: Pending Issue?

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2025

Search research articles

Related Experiment Videos

Calcium antagonists and renal failure progression.

Nicolás Roberto Robles¹

¹Hospital Infanta Cristina, Badajoz, Spain. nroblesp@senefro.org

|March 20, 2008

Summary

Newer calcium antagonists show promise in protecting kidneys from chronic renal failure. These drugs, including manidipine and lercanidipine, may reduce proteinuria and microalbuminuria, offering nephroprotective effects.

Area of Science:

Nephrology
Pharmacology
Cardiovascular Medicine

Background:

While tight blood pressure control is key for chronic renal failure, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer organ protection.
The specific renal effects of calcium antagonists are less defined, despite their potential pleiotropic kidney-protective actions.

Purpose of the Study:

To explore the nephroprotective mechanisms and clinical renal effects of calcium antagonists, particularly newer dihydropyridinic agents.
To evaluate the role of specific calcium antagonists like manidipine and lercanidipine in managing renal disease and proteinuria.

Main Methods:

Review of existing evidence on calcium antagonists' effects on kidney physiology.
Analysis of studies investigating the impact of manidipine and lercanidipine on proteinuria and microalbuminuria, including combination therapy.

Related Experiment Videos

Main Results:

Calcium antagonists exhibit pleiotropic effects, including attenuating mesangial entrapment, counteracting growth factor effects, and suppressing mesangial cell proliferation.
Newer dihydropyridinic calcium antagonists may decrease filtration fraction, offering nephroprotection comparable to renin-angiotensin axis blockers.
Manidipine and lercanidipine show potential in reducing proteinuria and microalbuminuria, with lercanidipine demonstrating efficacy in combination therapy.

Conclusions:

Newer calcium antagonists possess distinct nephroprotective properties beyond blood pressure reduction.
Manidipine and lercanidipine represent promising therapeutic options for patients with chronic renal failure, particularly in reducing proteinuria and microalbuminuria.